Thromb Haemost 1964; 11(01): 094-098
DOI: 10.1055/s-0038-1654809
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Evidence for Steroid Control of the Metabolism of Profibrinolysin

Authors

  • L. O Pilgeram

    1   Arteriosclerosis Research Laboratory, St. Barnabas Hospital Research Foundation and the Department of Physiology, University of Minnesota School of Medicine, Minneapolis, Minnesota
  • B. A Amundson

    1   Arteriosclerosis Research Laboratory, St. Barnabas Hospital Research Foundation and the Department of Physiology, University of Minnesota School of Medicine, Minneapolis, Minnesota
  • P. E Lofgren

    1   Arteriosclerosis Research Laboratory, St. Barnabas Hospital Research Foundation and the Department of Physiology, University of Minnesota School of Medicine, Minneapolis, Minnesota

This study has been supported in part by a research grant from G. D. Searle and Co., Chicago Illinois; the U.S. Public Health Service Grant No. H-3697; American, Iowa and Minnesota Heart Associations; the Life Insurance Medical Research Fund; and the University of Minnesota Graduate School.
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Preview

Summary

Daily therapy with 5 mg of norethynodrel and 0.075 mg of ethynylestra- diol-3-methyl ether (Enovid) is associated with a 34.7% (P < 0.001) increase in the activity of human serum profibrinolysin (plasminogen).